Cooley LLP announced today that it advised Horizon Pharma, Inc. on the completion of its acquisition of Vidara Therapeutics International plc. In connection with the acquisition, Horizon and Vidara have combined to form parent company Horizon Pharma plc, which is incorporated in Ireland. Concurrently with the acquisition, Horizon entered into a five-year $300 million term loan facility and related uncommitted facilities.

The acquisition further accelerates Horizon’s transformation into a profitable specialty biopharmaceutical company and provides a strong operating and financial platform for future growth. Cooley announced its representation of Horizon in its $600 million acquisition of Vidara in March 2014. View the press release here.

The Cooley team advising Horizon was led by partner and head of the firm’s M&A practice, Barbara Borden, and included partners Sean Clayton and Kay Chandler, and associates Ben Beerle, Wade Andrews, Scott Tanner, Matt Robbins and Dani Nazemian. Critical support was provided by partner Mark Hrenya and associate Michael Baker (tax); partner Gian-Michele a Marca, special counsel Barry Graynor and associates Jason Savich and Amanda Fant (credit finance); partner Chadwick Mills (securities); special counsel Michelle Lara and associate Justin Ho (compensation and benefits); partner Jackie Grise and associate Sharon Connaughton (antitrust); and special counsel Eric Kauffman (employment and labor).